Physician profile
Thomas T Ha
NPI 1568447860
$35,334.38
in general payments reported to CMS, 2019-2025
47 companies · $2,296 in 2025
The $2,296 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,604 · 2020: $4,258 · 2021: $5,427 · 2022: $3,216 · 2023: $7,013 · 2024: $9,520 · 2025: $2,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,774 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,050 · Travel and Lodging: $979 · Education: $25.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,774.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,050.00 |
| Travel and Lodging | $979.16 |
| Education | $25.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,288.51 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $3,224.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $2,059.23 | 2019-2023 | Epclusa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,550.67 | 2019-2025 | Jardiance |
| Amgen INC. | $1,341.36 | 2019-2025 | Evenity, Otezla, Prolia |
| Biohaven Pharmaceuticals, INC. | $1,240.44 | 2020-2021 | |
| Amarin Pharma, INC. | $1,192.18 | 2019-2022 | |
| Novo Nordisk INC | $948.77 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $721.53 | 2020-2025 | |
| Pfizer INC. | $609.75 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $607.33 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $582.70 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $522.84 | 2022-2025 | |
| Lilly USA, LLC | $395.52 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $371.19 | 2019-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.